STOCK TITAN

Nrx Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.

NRX Pharmaceuticals Inc (NRXP) provides investors and healthcare professionals with critical updates on novel therapies for central nervous system disorders and pulmonary diseases. This page aggregates official press releases, clinical trial developments, and regulatory milestones related to the company’s NMDA platform and ketamine-based treatments.

Visitors gain access to verified information about NRX-100 and NRX-101 – investigational therapies targeting suicidal depression and bipolar disorder – along with strategic initiatives through subsidiary HOPE Therapeutics. The resource prioritizes clarity in explaining complex biopharmaceutical concepts while maintaining scientific precision.

Key content includes updates on Fast Track designations, New Drug Application progress, and innovations in preservative-free drug formulations. The curated news collection serves as a decision-making tool for tracking the company’s progress in addressing unmet medical needs through rigorous clinical research.

Bookmark this page for streamlined access to NRX Pharmaceuticals’ latest developments in interventional psychiatry and small-molecule therapeutics. Check regularly for authoritative updates on pipeline advancements and regulatory strategy execution.

Rhea-AI Summary

IQVIA announced a significant collaboration with NRx Pharmaceuticals to support pharmacovigilance and medical information for the potential emergency use authorization (EUA) of ZYESAMI, a treatment for COVID-19 patients. This partnership leverages IQVIA's extensive data and analytics capabilities to enhance compliance and support regulatory actions as the pandemic continues. NRx appreciates IQVIA's global reach, which will assist in delivering critical treatments to patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.12%
Tags
covid-19
-
Rhea-AI Summary

NRx Pharmaceuticals (NRXP) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The event will include a virtual on-demand presentation and one-on-one investor meetings, with the presentation available starting September 13 at 7 AM EST. NRx is developing treatments for COVID-19 and bipolar depression, with investigational products ZYESAMI™ and NRX-101 currently in advanced trials. The company leverages extensive experience from executives with backgrounds at major pharmaceutical firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
conferences
-
Rhea-AI Summary

NRx Pharmaceuticals (NRXP) has entered a partnership with Cardinal Health to facilitate third-party logistics and distribution for its drug ZYESAMI™ pending potential Emergency Use Authorization (EUA) from the FDA. This agreement is expected to enhance access to ZYESAMI™ for patients with Critical COVID-19, leveraging Cardinal Health's extensive distribution network, which covers over 90% of U.S. hospitals. The deal aims to expedite treatment for COVID-19 patients in critical care, aligning with NRx's ongoing FDA application process for ZYESAMI™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) has successfully completed a private placement, raising $30 million by selling 2,727,273 shares of common stock at $11.00 each. Investors also received unregistered preferred investment options, exercisable at $12.00 for three years. This funding is intended to advance three late-stage assets, including a Fast Track treatment for severe COVID-19 cases, a vaccine targeting COVID-19 variants, and a therapy for suicidal bipolar depression and PTSD. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
none
-
Rhea-AI Summary

NRx Pharmaceuticals (NRXP) reported that participants in the high-dose BriLife vaccine trial for COVID-19 have been informed they do not require a booster dose, as their immunity remains robust six months post-second dose. In contrast, those who received lower doses are advised to get a booster from Pfizer or Moderna. CEO Prof. Jonathan Javitt indicated preparations for a Phase 2b/3 protocol submission for BriLife are underway. The vaccine is a self-propagating, live-virus variant designed to adapt against evolving COVID-19 strains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.7%
Tags
covid-19
-
Rhea-AI Summary

NRx Pharmaceuticals (NRXP) announced a definitive agreement for a private placement to raise approximately $30 million by selling 2,727,273 shares at $11.00 each, along with associated investment options. The offering, managed by H.C. Wainwright & Co., is expected to close by August 23, 2021. Proceeds will support the development of the CNS/psychiatry and COVID vaccine franchises, and transition of ZYESAMI to commercial stages as regulatory approval progresses. The offering is not registered under the Securities Act, limiting its sale in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.21%
Tags
none
Rhea-AI Summary

NRx Pharmaceuticals (NRXP) announced a safety update for ZYESAMI™ (aviptadil), confirming no new safety concerns during the NIH-sponsored ACTIV-3 Critical Care Phase 3 study. The Data Safety Monitoring Board reviewed data from approximately 140 patients and recommended continued enrollment. ZYESAMI™ is being tested alongside remdesivir in hospitalized COVID-19 patients requiring high-flow oxygen. This study is one of three ongoing trials for ZYESAMI™ in critical COVID-19 cases. NRx holds FDA Fast Track designation and Breakthrough Therapy Designation for ZYESAMI™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
covid-19
-
Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) reported its second-quarter 2021 results, marking its first quarterly update as a public company. The company submitted an EUA request for its COVID-19 treatment ZYESAMI on May 31 and expects initial orders from Georgia soon. NRx also announced a partnership with the Israeli Institute for Biological Research for the BriLife COVID vaccine. Financially, NRx reported a net loss of $16 million, primarily due to increased R&D and G&A expenses, and had cash reserves of $13.4 million as of June 30, 2021. The next conference call is set for August 17, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.49%
Tags
none
-
Rhea-AI Summary

NRx Pharmaceuticals (NASDAQ: NRXP) will announce its second quarter 2021 financial results on August 16, 2021, after market close. A conference call is scheduled for August 17, 2021, at 8:30 AM ET, where management will discuss results and provide updates. Investors can join via phone or a live audio webcast. NRx focuses on developing therapies for serious conditions, including COVID-19 treatment ZYESAMI, which has received FDA Fast Track Designation and is in phase 3 trials. They are also developing NRX-101 for bipolar depression, with readouts expected in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences
Rhea-AI Summary

NRx Pharmaceuticals (NRXP) announced it will ring the Nasdaq Closing Bell on August 10, 2021, marking its listing celebration. CEO Jonathan Javitt highlighted the occasion alongside their recent grant of Emergency Use for ZYESAMI™ for COVID-19 and initiation of international vaccine trials. The FDA granted Fast Track Designation for ZYESAMI™ with ongoing Phase 2b/3 trials. Additionally, NRx secured worldwide rights to develop the BriLife™ COVID vaccine and is progressing with NRX-101 for bipolar depression, which also holds Breakthrough Therapy Designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
none
Nrx Pharmaceuticals Inc

NYSE:NRXP

NRXP Rankings

NRXP Stock Data

32.65M
14.03M
17.08%
6.2%
6.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
WILMINGTON